Spots Global Cancer Trial Database for measurable residual disease

Every month we try and update this database with for measurable residual disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MRD Response-adapted Allo-HSCT for Adverse-risk AML	NCT06301425	Acute Myeloid L...	Intervention gr... Control group	16 Years - 65 Years	Peking University People's Hospital
Risk-adapted Therapy for Primary Acute Myeloid Leukemia	NCT04687098	Leukemia, Myelo...	Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi...	17 Years - 70 Years	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
The clonoSEQ® Watch Registry	NCT04545333	Acute Lymphobla... Chronic Lymphoc... Multiple Myelom... Non-hodgkin Lym...	clonoSEQ Assay	18 Years -	Adaptive Biotechnologies
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	NCT05904106	Acute Myeloid L...	Venetoclax plus... standard of car...	18 Years - 70 Years	Technische Universität Dresden
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.	NCT05203003	Multiple Myelom...	Assessment of M...	18 Years -	Assistance Publique - Hôpitaux de Paris
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.	NCT05203003	Multiple Myelom...	Assessment of M...	18 Years -	Assistance Publique - Hôpitaux de Paris
Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival	NCT03549351	Leukemia, Myelo...	Measurable resi...	-	University Hospital Heidelberg
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse	NCT06000306	Measurable Resi...	Digital Droplet...	12 Years - 70 Years	Zhejiang University
MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse	NCT06000306	Measurable Resi...	Digital Droplet...	12 Years - 70 Years	Zhejiang University
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	NCT05904106	Acute Myeloid L...	Venetoclax plus... standard of car...	18 Years - 70 Years	Technische Universität Dresden
Risk-adapted Therapy for Primary Acute Myeloid Leukemia	NCT04687098	Leukemia, Myelo...	Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi...	17 Years - 70 Years	Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
The clonoSEQ® Watch Registry	NCT04545333	Acute Lymphobla... Chronic Lymphoc... Multiple Myelom... Non-hodgkin Lym...	clonoSEQ Assay	18 Years -	Adaptive Biotechnologies

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: